No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: European Commission Approves Galderma’s Nemolizumab
On 14 February 2025, Galderma announced that the European Commission has approved Nemluvio® (nemolizumab) for both moderate to severe atopic dermatitis and prurigo nodularis.